Journal
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 85, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.intimp.2020.106645
Keywords
Ginsenosides Rk3; Ulcerative colitis; Inflammation; Tight junctions; Short-chain fatty acids; NLRP3
Categories
Funding
- National Natural Science Foundation of China [21676214, 21878246, 21808184]
Ask authors/readers for more resources
Ginsenosides have a variety of pharmacological activities, including immunomodulatory, antitumor and anti-inflammatory activities. However, the effect of Rk3 on ulcerative colitis has rarely been reported. This study evaluated the effect of Rk3 on DSS-induced ulcerative colitis and preliminarily explored the anti-inflammatory mechanisms. Rk3 administration significantly attenuated the weight loss, increased DAI scores, colonic shortening, and increased MPO and iNOS activities caused by DSS in mice. Histological improvement was apparent, tight junctions in the colon were restored, and the levels of short-chain fatty acids (acetic acid, butyric acid and isovaleric acid) were increased. In addition, Rk3 reduced the expression of proinflammatory factors (TNF-alpha, IL-1 beta and IL-6), NLRP3, ASC, and Caspase-1, indicating blockade of the NLRP3 inflammasome pathway. These results show that Rk3 can improve DSS-induced ulcerative colitis by protecting intestinal barrier function and inhibiting NLRP3 inflammasome expression, indicating that Rk3 could be used as a potential drug for treating ulcerative colitis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available